Cori Passer, MD
Allergy & Immunology · Overland Park, KSNPI 1902902497
Payments from drug & device makers
Across 615 payments — averaging $22.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$2K
- GSK$1K
- Sanofi$1K
- Genentech USA, Inc.$1K
- Novartis$895
- plus $6K from 30 others
What the payments were for
- Consulting fees$580%
- Food & beverage$13,36798%
- Education$1561%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 83 | $1,693 |
| Regeneron Healthcare Solutions, Inc. | 56 | $1,611 |
| GSK | 71 | $1,216 |
| Sanofi | 29 | $1,129 |
| Genentech USA, Inc. | 55 | $1,106 |
| Novartis | 32 | $895 |
| Pfizer | 23 | $532 |
| AbbVie(2 entities) | 42 | $530 |
| Hospira, Inc. | 32 | $474 |
| Amgen | 19 | $473 |
| CSL Behring | 20 | $438 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $429 |
| LEO Pharma Inc. | 16 | $345 |
| Grifols USA, LLC | 15 | $344 |
| Optinose US, Inc. | 6 | $321 |
| Pharming Healthcare, Inc. | 18 | $319 |
| Incyte Corporation | 2 | $243 |
| Blueprint Medicines Corporation | 7 | $208 |
| Bio Products Laboratory USA, Inc. | 10 | $185 |
| Galderma Laboratories, L.p. | 4 | $155 |
| Biocryst US Sales Co., LLC | 6 | $122 |
| Boehringer Ingelheim | 6 | $98 |
| ADMA Biomanufacturing LLC | 5 | $91 |
| Alk-abello, Inc | 4 | $88 |
| Kaleo, Inc. | 5 | $85 |
| Sunovion Pharmaceuticals Inc. | 4 | $83 |
| Octapharma USA, Inc. | 3 | $66 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $60 |
| Hikma Pharmaceuticals USA | 3 | $55 |
| Lilly USA, LLC | 3 | $51 |
| Teva Pharmaceuticals USA, Inc. | 3 | $35 |
| Merck | 2 | $30 |
| Shire North American Group Inc | 2 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| GC Biopharma USA, Inc. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,582 in reported general payments places this provider in the 55th percentile of 33 allergy & immunology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 137 | $106,347 |
| Breo ElliptaFluticasone/Vilanterol | 79 | $41,613 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $32,531 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 102 | $22,447 |
| SymbicortBudesonide/Formoterol Fumarate | 47 | $15,316 |
| Advair HfaFluticasone Propion/Salmeterol | 31 | $14,907 |
| Azelastine Hcl | 245 | $9,748 |
| Wixela InhubFluticasone Propion/Salmeterol | 38 | $7,831 |
| Ipratropium Bromide | 200 | $7,466 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 37 | $7,376 |
| DuleraMometasone/Formoterol | 22 | $6,952 |
| Arnuity ElliptaFluticasone Furoate | 13 | $6,576 |
| Fluticasone Propionate HfaFluticasone Propionate | 14 | $3,830 |
| Montelukast Sodium | 371 | $3,678 |
| Epinephrine | 20 | $3,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,216 | $154,536229 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,693 | $47,84782 claims |
| MerckDulera | $30 | $6,95222 claims |
| Hikma Pharmaceuticals USAEpinephrine | $55 | $3,39120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 33 allergy & immunology providers in Kansas.
Other allergy & immunology in Overland Park
- William LaveryOverland Park$16.9M
- Derrick WardOverland Park$2.9M
- Henry KanarekOverland Park$740K
- Celina BernabeOverland Park$95K
- James SternerOverland Park$92K
- Jeffrey WaldOverland Park$86K
- Mark NeustromOverland Park$82K
- Sara AzzamOverland Park$19K
- Nguyen TranOverland Park$15K
- H LevineOverland Park$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.